张立胜 惠正刚 胡明贤 张映红 周小兰.阿奇霉素联合孟鲁司特钠治疗儿童肺炎支原体肺炎的临床研究[J].,2015,15(15):2910-2912 |
阿奇霉素联合孟鲁司特钠治疗儿童肺炎支原体肺炎的临床研究 |
The Clinical Research of Azithromycin Combined with Montelukast in theTreatment of Children with Mycoplasma Pneurnoniae Pneumonia |
|
DOI: |
中文关键词: 阿奇霉素 孟鲁司特钠 哮喘 小儿支原体肺炎 |
英文关键词: Azithromycin Montelukast Asthma MMP |
基金项目: |
|
摘要点击次数: 735 |
全文下载次数: 0 |
中文摘要: |
目的:探讨阿奇霉素联合孟鲁司特钠治疗儿童肺炎支原体肺炎(MMP)的疗效。方法:选取2013 年3 月至2014 年3月收治的
100例MMP 患儿,将其随机分为对照组和实验组各50 例,对照组采用静脉滴注阿奇霉素治疗,实验组在对照组基础上口服孟鲁
司特钠片。比较两组患儿的治疗效果、哮喘发生率及不良反应。结果:实验组患儿治疗后退热时间、止咳时间、住院时间分别为
(1.69± 0.99)d、(3.39± 1.48)d、(6.15± 2.02)d,明显低于对照组的(3.95± 2.45)d、(5.92± 3.32)d、(8.86± 1.78)d,差异均有统计学
意义(均P<0.05);实验组患儿儿童支原体肺炎诱发哮喘的发病率为10%(5/50),显著低于对照组的48%(24/50),差异有统计学
意义(P<0.05);两组在治疗过程中均未见明显不良反应。结论:阿奇霉素联合孟鲁司特钠治疗儿童MMP 能明显提高患者的治疗
效果,且能有效降低儿童支原体肺炎诱发哮喘的发病率,值得临床推广。 |
英文摘要: |
Objective:To observe the efficacy of Azithromycin combined with Montelukast in the treatment of children with Mycoplasma
Pneurnoniae Pneumonia (MMP).Methods:Selected 100 cases of children with MMP from March 2013 to March 2014, which
were divided into the control group and the experimental group with 50 cases in each group. The control group were treated with
Azithromycin, while the experimental group were given oral Montelukast Sodium tablets treatment on the basis of the control group at
the same time. Compared the therapeutic effect, the incidence of asthma and adverse reaction between two groups.Results:The defervesce
time, relieve cough time and hospitalization time of experimental group was (1.69± 0.99)d, (3.39± 1.48)d, was (6.15± 2.02)d, respectively,
was significantly lower than those in the control group (3.95± 2.45)d, (5.92± 3.32)d, (8.86± 1.78)d, the difference had statistical
significance (all P<0.01). The incidence rate of asthma induced by mycoplasma pneumonia was 10%(5/50) in experimental group,
was significantly lower than 48%(24/50) of the control group, the difference was statistically significant(P<0.01). There was no obvious
adverse reaction in two groups during treatment.Conclusion:Azithromycin combined with Montelukast in the treatment of children with
MMP can significantly improve treatment, and effectively reduce the incidence rate of asthma induced by mycoplasma pneumonia in
children, it is worthy of clinical promotion . |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|